

WO 98/56821

PCT/AT98/00130

## C l a i m s :

1. A native chromatographically purified  $\alpha_1$ -AT preparation, characterized in that it contains at least the isomer having a pI value of between 4.3 and 4.4, has a purity of at least 0.7 PU/mg protein and a relative plasma- $\alpha_1$ -AT activity of at least 120% and that its portion of inactive  $\alpha_1$ -AT is less than 10%.
2. A preparation according to claim 1, characterized in that it is present as a pharmaceutical preparation.
3. A preparation according to claim 1 or 2, characterized in that it is purified from a plasma pool.
4. A preparation according to any one of claims 1 to 3, characterized in that it has a purity of more than 0.9 PU/mg, preferably more than 1.0 PU/mg, in particular more than 1.1 PU/mg.
5. A preparation according to claim 4, characterized in that it has a purity of more than 1.2 PU/mg.
6. A preparation according to any one of claims 1 to

WO 98/56821

PCT/AT98/00130

5, characterized in that its portion of inactive  $\alpha$ 1-AT is less than 5%, in particular less than 2%.

7. A preparation according to any one of claims 1 to 6, characterized in that it is free from inactive  $\alpha$ 1-AT.

8. A preparation according to any one of claims 1 to 7, characterized in that the  $\alpha$ 1-AT is a preservative one.

9. A preparation according to any one of claims 1 to 8, characterized in that the isomer distribution of the  $\alpha$ 1-AT corresponds to that of native protein, in particular to a quadruplet band pattern visible at isoelectric focussing.

European Patent Document